focus -WSS

focus

author：focus 2025-09-29 22:49:28 - browse：932

CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers applying for approval with data from trials solely run in a single country such as China, but instead wants to see companies conducting studies across the world.

The comments by Richard Pazdur, director of the FDA’s Oncology Center of Excellence, came as more drugmakers report data from China, with Miami-based Summit Therapeutics earlier this week announcing that its investigational drug beat Merck’s blockbuster Keytruda in a head-to-head non-small cell lung cancer study in China.

It’s not a blanket policy, and the agency would assess each company’s submission to see how applicable the data are to the U.S. population, but in general, “I am pro multi-regional trials,” Pazdur said Friday at STAT@ASCO, STAT’s event at the American Society of Clinical Oncology annual meeting.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Bring on the sabbaticals for nurses

WSS

Cancer drug shortages should be causing more outrage

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Dobbs anniversary: the lost opportunity of abortion as health care

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Wildfire smoke exposes gaps in outdoor worker protections

After affirmative action ruling, medical educators look to 'holistic review'

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Cancer drug shortages should be causing more outrage

Peter Hotez and the public health issue of online harassment

Chinese researcher claims birth of first gene

Tori Bowie and the unacceptable rates of Black maternal death

Guidelines to prevent youth baseball injuries need more muscle

The high cost of giving birth even with insurance

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Medical records are filled with copy

Testing GLP

focus

Virginia high school admissions case could be legal follow

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Trump demands the U.S. pay no more for drugs than other countries … again

This gene therapy has record $4.25 million price. It's saved children.

In age of alternative facts, a scholarly course on calling out crap

hotspot

knowledge

hotspot

focus